TGA · AHPRA · FSANZ · ACCC

Last reviewed: September 2025

Telehealth Advertising Compliance Australia 2025 — TGA · AHPRA · ACCC

Introduction

Telehealth has changed how Australians access healthcare, and it has changed the compliance problem too. A telehealth platform's website is simultaneously a consumer-facing advertisement, a practitioner-attributed health resource, and a digital front-end for accessing prescription-only treatments. Each of those functions attracts a different regulatory framework. Failing to navigate all three at once is where the compliance risk sits.

The enforcement context is stark. AHPRA assessed 775 advertising complaints in 2024–25 — up 104% in two years. A growing proportion of those complaints involve digital advertising for telehealth services: condition landing pages that imply diagnosis, consult funnels that imply guaranteed outcomes, and testimonials from patients who describe the results of their treatment. The TGA adds a second layer: if a telehealth platform's content refers to, implies, or enables access to prescription medicines, the Schedule 4 advertising prohibition in s.42DL of the TGA Act applies — regardless of whether the platform itself employs the prescribers.

1. The regulatory framework for telehealth content

Telehealth advertising compliance sits across three frameworks that interact differently depending on what the content is doing.

AHPRA Advertising Guidelines — the primary framework for practitioner-attributed content Where registered health practitioners are named, featured, or identifiably associated with a telehealth platform's advertising, the AHPRA guidelines apply. This covers: GP telehealth services, psychologist platforms, physiotherapy and allied health platforms, and any service marketed as "doctor-led", "clinician-reviewed", or "practitioner-delivered." Key obligations:

• Section 133(1)(c) of the National Law: testimonials from patients or clients are prohibited. This is an absolute prohibition — it extends to social media reviews, before/after stories, and patient outcome quotes in email campaigns.
• AHPRA Guidelines §4: advertising must not claim, imply, or create a reasonable expectation of beneficial results from treatment where those results cannot be guaranteed.
• AHPRA Guidelines §5: qualifications must be accurately stated. "Doctor" in a consumer-facing context implies a registered medical practitioner — not a PhD, not an overseas-trained clinician without AHPRA registration.
• AHPRA Guidelines §6: advertising must not create unrealistic expectations about treatment. "Get your prescription today" creates an expectation that a prescription will be issued regardless of clinical assessment — this is a guaranteed outcome claim.

Therapeutic Goods Act 1989, s.42DL — Schedule 4 advertising prohibition Telehealth platforms that treat erectile dysfunction, weight management, hair loss, skin conditions, or mental health conditions frequently involve prescription-only (Schedule 4) medicines as part of the treatment pathway. Any consumer-facing content that names, describes, or implies access to specific Schedule 4 medicines is a criminal offence under s.42DL, regardless of whether the content appears on a medical platform. This includes: condition pages that list branded prescription treatments, email flows that reference specific medications after a consultation, and social ads targeting users who have viewed prescription treatment landing pages.

Australian Consumer Law, s.18 — misleading or deceptive conduct All health outcome claims in telehealth advertising are subject to the ACL prohibition on misleading or deceptive conduct. Claims that imply a higher probability of positive outcomes than the evidence supports, that describe treatment outcomes as guaranteed or typical, or that fail to disclose material limitations are s.18 breaches. This applies to conversion-optimised copy regardless of technical accuracy — a truthful statement that creates a false overall impression is still a breach.

2. Condition pages — what can and cannot be said

Condition pages are the high-traffic entry points for most telehealth platforms. They target people searching for symptoms or diagnoses and connect them to the platform's consultation pathway. They are also the most frequently non-compliant page type in telehealth.

What is permitted on a condition page:

• Factual, balanced information about a medical condition — its definition, prevalence, established treatment approaches, and when to seek professional assessment
• Information about the platform's consultation process, the types of practitioners available, and how to access an assessment
• General descriptions of treatment categories (e.g. "medication, lifestyle changes, and therapeutic support") without naming specific scheduled medicines

What is prohibited on a condition page:

• Claims that imply diagnosis without a consultation ("If you have these symptoms, you likely have X")
• Statements that create an expectation of a specific treatment outcome ("Most patients see improvement within 4 weeks")
• Named references to Schedule 4 medicines as treatments available through the platform
• Patient stories or testimonials describing outcomes from treatment

The line between "factual information about a condition" and "an implied guarantee of treatment" is crossed when the page's primary commercial purpose — acquiring consultation bookings — causes it to frame clinical information in outcome-predictive terms. A condition page that says "most patients with this condition respond well to treatment" is making a statistical outcome claim. That claim must be substantiated, must accurately represent the evidence base, and must not imply that the platform's specific treatment will produce those results.

3. Treatment claims — the rules for describing what you offer

Treatment landing pages on telehealth platforms describe what a consultation may lead to — the therapeutic interventions a registered practitioner might recommend. The compliance challenge is that outcome-predictive framing of these interventions is prohibited under both AHPRA guidelines and the ACL, even where the treatments themselves are clinically established.

Permitted framing: "Our practitioners assess each patient individually. Where clinically appropriate, treatment options may include [category description]."

Prohibited framing: "Get the treatment that works. Our doctors prescribe [named treatment] to help you [outcome]." Three separate violations in one sentence: a guaranteed outcome claim, a potential Schedule 4 named-product reference, and an implied result.

Specific treatment claim violations common in telehealth:

"Clinically proven" without qualification. A treatment may be clinically established in the medical literature. Claiming it is "clinically proven" in consumer advertising without specifying what it is proven to do, in what population, and with what success rate creates a misleading impression under the ACL. The phrase "clinically proven" should not be used in consumer-facing telehealth advertising without direct and precise qualification.

Success rate claims. Stating that a treatment has an "X% success rate" in advertising creates a reasonable expectation of individual outcome. Unless the advertiser can demonstrate that the stated rate applies to their platform's patient cohort under comparable conditions, this is an ACL breach. General population success rates from clinical trials do not substantiate platform-specific claims.

Before/after comparisons. AHPRA's guidelines explicitly address before/after imagery in advertising for regulated health services. Where the before/after comparison implies a guaranteed clinical outcome, it is a prohibited claim. This applies to images, video, and written descriptions (e.g. "from struggling to thriving in 6 weeks").

4. Consult funnels — compliance across the conversion pathway

Telehealth consult funnels — the multi-step flows that move a user from landing page to consultation booking — create compliance risk at every conversion-optimised step. The pressure to reduce drop-off at each step frequently results in copy that makes implied guarantees, names scheduled medicines, or uses outcome-predictive language.

Step-by-step compliance risks:

The quiz or symptom checker. Many telehealth platforms use a short questionnaire to qualify leads and personalise the funnel. Quiz copy that frames the outcome as "you're a good candidate for treatment" or "our doctors commonly prescribe X for your profile" is a prohibited outcome guarantee and, where X is a Schedule 4 medicine, also a TGA breach.

The appointment confirmation page. Copy that says "you're on your way to feeling better" or "most patients see results after their first consultation" is an outcome guarantee in disguise. Removing these from conversion confirmation pages eliminates a frequently flagged AHPRA issue.

The email follow-up sequence. Post-consultation emails that name the prescribed treatment, describe its expected outcomes, or include patient success content trigger both the Schedule 4 advertising prohibition and the AHPRA testimonial ban. These emails are advertising under both frameworks regardless of the transactional framing.

Retargeting campaigns. A telehealth platform that retargets users who visited a specific condition page with ads referencing that condition and implying access to treatment is running condition-targeted advertising. Where that advertising pathway leads to or implies Schedule 4 treatment, the retargeting itself may be a s.42DL breach.

5. Common telehealth advertising compliance mistakes

MISTAKE — Using patient testimonials as social proof PROBLEM — Where a telehealth platform provides services by registered practitioners, patient testimonials are absolutely prohibited under s.133(1)(c) of the National Law. This applies regardless of whether the testimonial is on the website, in an email campaign, or in a paid social ad. A positive Google Review that describes a treatment outcome is a testimonial if it is reproduced or promoted by the platform. FIX — Remove all patient testimonials and outcome-describing reviews from all advertising channels. Use factual outcome statistics at the population level (where evidence-based) and describe the consultation process rather than treatment results.

MISTAKE — Naming prescription treatments on condition pages PROBLEM — Condition pages for hair loss, ED, weight management, or anxiety frequently name specific Schedule 4 medicines as treatments available through the platform. This is a criminal offence under s.42DL of the TGA Act regardless of the platform's medical nature. FIX — Describe treatment categories (medication, lifestyle support, therapeutic approaches) without naming specific scheduled products. Move product-level information into the post-consultation, authenticated patient environment only.

MISTAKE — Implied diagnosis through symptom-check framing PROBLEM — Copy that says "if you have these 3 symptoms, you may have X" leads consumers toward a self-diagnosis before any clinical assessment. AHPRA's guidelines prohibit advertising that creates unrealistic expectations about diagnosis or treatment. This type of copy also risks creating health detriment under the ACL if it results in consumers seeking treatment they may not need. FIX — Frame symptom information as "conditions our practitioners assess" rather than diagnostic criteria. Always include "a clinical assessment is required to determine whether treatment is appropriate" adjacent to any symptom content.

Compliant vs non-compliant examples

Penalty reference

Pre-publish checklist

TGA — Schedule 4 advertising prohibition

AHPRA — Practitioner-attributed content

ACL

Related guides

→ Aesthetic & Cosmetic Clinic Advertising Compliance → Online Pharmacy Advertising Compliance → Naturopath & Allied Health Advertising Compliance → What does AHPRA's ban on testimonials actually cover?

How CompliGUARD automates this check

CompliGUARD reviews telehealth marketing content — condition pages, treatment descriptions, consult funnel copy, and email sequences — against AHPRA · TGA · ACCC requirements simultaneously. Every review is assessed against the specific obligations that apply to practitioner-attributed advertising, including the testimonial prohibition under s.133(1)(c) of the National Law, the Schedule 4 advertising prohibition under TGA s.42DL, and the misleading conduct provisions of the ACL. Each review returns a clause-cited compliance report, a risk rating (low/medium/high), specific issue flags, and a compliant rewrite. Every review is stored in a tamper-evident audit vault.

Key takeaways

1. Condition pages must describe conditions factually without implying diagnosis, guaranteed outcomes, or access to specific Schedule 4 medicines.
2. Patient testimonials are absolutely prohibited in telehealth advertising where registered practitioners are involved — this extends to Google reviews, social content, and email campaigns.
3. Consult funnel copy at every step — quiz, confirmation, email follow-up — is advertising and must comply with AHPRA guidelines and the ACL.
4. Schedule 4 medicines cannot be named or described in consumer-facing telehealth advertising, regardless of the platform's clinical nature.
5. "Clinically proven" and success rate claims require precise substantiation — general clinical trial data does not support platform-specific advertising claims.

Regulatory references

• Health Practitioner Regulation National Law Act 2009, s.133 (advertising restrictions — testimonial prohibition)
• AHPRA Advertising Guidelines, December 2020, §4 (beneficial outcomes)
• AHPRA Advertising Guidelines, December 2020, §5 (qualifications)
• AHPRA Advertising Guidelines, December 2020, §6 (unrealistic expectations)
• Therapeutic Goods Act 1989 (Cth), s.42DL (prohibited advertisements — scheduled medicines)
• Australian Consumer Law (Schedule 2, Competition and Consumer Act 2010), s.18 (misleading or deceptive conduct)
• Therapeutic Goods Advertising Code 2021 (Cth), s.17 (testimonial restrictions — therapeutic goods)

CompliGUARD provides compliance insights based on TGA, FSANZ, ACCC and AHPRA guidance as current at the time of review. The Therapeutic Goods Advertising Code is currently under formal review by the TGA (2025–26). This output does not constitute legal advice.